Abstract:COVID-19 is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), and according to the World Health Organization (WHO), to date, SARS-CoV-2 has already infected more than 91.8 million people worldwide with 1,986,871 deaths. This virus affects mainly the respiratory system, but the gastrointestinal tract (GIT) is also a target, meanwhile SARS-CoV-2 was already detected in oesophagus, stomach, duodenum, rectum, and in fecal samples from COVID-19 patients. Prolonged GIT manifestations in COVID-19, mainly the diarrhea, were correlated with decreased richness and diversity of the gut microbiota, immune deregulation and delayed SARS-CoV-2 clearance. So, the bidirectional interactions between the respiratory mucosa and the gut microbiota, known as gut-lung axis, are supposed to be involved in the healthy or pathologic immune responses to SARS-CoV-2. In accordance, the intestinal dysbiosis is associated with increased mortality in other respiratory infections, due to an exacerbated inflammation and decreased regulatory or anti-inflammatory mechanisms in the lungs and in the gut, pointing to this important relationship between both mucosal compartments. Therefore, since the mucous membranes from the respiratory and gastrointestinal tracts are affected, in addition to dysbiosis and inflammation, it is plausible to assume that adjunctive therapies based on the modulation of the gut microbiota and re-establishment of eubiosis conditions could be an important therapeutic approach for constraining the harmful consequences of COVID-19. Then, in this review, we summarized studies showing the persistence of SARS-CoV-2 in the gastrointestinal system and the related digestive COVID-19 manifestations, in addition to the literature demonstrating nasopharyngeal, pulmonary and intestinal dysbiosis in COVID-19 patients. Lastly, we showed the potential beneficial role of probiotic administration in other respiratory infections, and discuss the possible role of probiotics as an adjunctive therapy in SARS-CoV-2 infection.

The Microbiota/Host Immune System Interaction in the Nose to Protect from COVID-19

The Microbiota/Host Immune System Interaction in the Nose to Protect from COVID-19

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection

Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment

Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection

Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Intestinal Flora As a Potential Strategy to Fight SARS-CoV-2 Infection

Immunomodulatory Effects of Probiotics on COVID-19 Infection by Targeting the Gut–Lung Axis Microbial Cross-Talk

Microbiota Modulation of the Gut-Lung Axis in COVID-19

Potential Associations Between Microbiome and COVID-19

Microbiota and Its Impact on the Immune System in COVID-19—A Narrative Review

Respiratory syndrome coronavirus-2 response: Microbiota as lactobacilli could make the difference

Profiling of Oral Microbiota and Cytokines in COVID-19 Patients

From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract

Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection

Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19

Assessment of Microbiota in the Gut and Upper Respiratory Tract Associated with SARS-CoV-2 Infection